KEVIN KREBS: Open Payments
NPI 1730159047 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 57 payments from 11 companies in 2025. Trend: 2023 $1,246 · 2024 $1,370 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $228 |
| Axsome Therapeutics, Inc. | 7 | $150 |
| Alkermes, Inc. | 6 | $148 |
| Supernus Pharmaceuticals, Inc. | 6 | $129 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $118 |
| Tris Pharma Inc | 5 | $100 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Noven Therapeutics, LLC | 1 | $24 |
| Neos Therapeutics, LP | 1 | $21 |
Products named: VRAYLAR, Auvelity, Qelbree, CAPLYTA, LYBALVI, Dyanavel XR, Jornay PM, REXULTI.
Industry payments across SC — which companies pay providers there.
